Inhibrx Biosciences, Inc. (INBX) SEC Filings & Earnings Calls

Clinical trial risk; data from early-stage study; regulatory path uncertain

“Phase 2 expansion; potential accelerated approval path but not guaranteed”

Clinical trial risk: Phase 2 data positive but still early; need to expand and confirm in Phase 3.

“plans to expand the randomized Phase 2 portion... by approximately 50 additional HPV+ OPSCC patients... to support a potential accelerated regulatory pathway”

No Approved Products / Revenue

“As of the date of this Quarterly Report, all of our revenue has been derived from licenses with collaboration partners and grant awards. We have not generated any revenue from the commercial sale of approved therapeutic products to date.” · word for word

High Cash Burn and Debt

“Net cash used in operating activities was $67.9 million during the six months ended June 30, 2026.” · word for word

Clinical and Regulatory Uncertainty

“We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development.” · word for word

Increasing net loss and cash burn; no revenue in Q2 2026.

“Net loss was $36.7 million during the second quarter of 2026, compared to $28.7 million in the prior year period. The Company did not recognize any revenue during the second quarter of 2026.” · word for word

Dilution risk from warrant issuance

“Warrants to purchase 21,457 shares at $93.21 per share, plus additional warrants for Term D.”

Debt service and covenant risk

“Loan agreement includes customary covenants, minimum liquidity of $20M, and variable interest rate (SOFR + 5.50% with 3.25% floor).”

Clinical trial failure risk

“We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development.” · word for word

Capital need risk

“We will need substantial additional capital in the future to support these efforts.” · word for word

No approved products

“We have not generated any revenue from the commercial sale of approved therapeutic products to date.” · word for word

Clinical trial failure risk for INBRX-106 and ozekibart; dependency on regulatory approvals.

“Pipeline candidates in early-to-mid stage trials; BLA submitted for ozekibart in chondrosarcoma but approval uncertain.”

High cash burn rate with no revenue; reliance on debt financing increases interest expense.

“Other expense increased to $2.5M from $0.4M due to higher interest on $175M loan balance.”

Dependence on clinical trial success

“The Company’s 2025 performance goals generally fell into the categories of executing on the progression of our clinical programs” · word for word

Concentration of ownership

“Entities affiliated with Viking Global Opportunities Illiquid Investments Sub-Master LP 10.05%; Entities affiliated with Perceptive Life Sciences Master Fund, Ltd. 9.99%” · word for word

Forward-looking statement risks: topline data may not reflect final results; regulatory approval not guaranteed; competition may impact prospects.

“Cautionary language regarding forward-looking statements.”

Cash burn; reliance on debt financing; clinical trial risks for ozekibart and INBRX-106.

“Cash and cash equivalents $124.2M; additional $75M debt; R&D expenses decreasing as trials near completion; upcoming milestones for BLA submission and data readouts.”

Hepatotoxicity risk for ozekibart

“Hepatotoxicity, a known risk for this mechanism of action, occurs during the first treatment cycle and is in patients with underlying hepatic impairment. One hepatotoxicity-related fatal event occurred early in the study, prior to the implementation of mitigation measures.” · word for word

Clinical trial failure for INBRX-106

“INBRX-106 is still in Phase 2/3 trials; data not yet mature; risk of failure.”

Pre-revenue biotech with pipeline dependency; ozekibart transaction on pause.

“A potential ozekibart transaction is on pause” · word for word

Pre-revenue clinical-stage company with significant ongoing losses

“We have not generated any revenue from the commercial sale of approved therapeutic products to date.” · word for word

Dependence on successful clinical development and regulatory approval

“We plan to submit to the FDA a biologics license application in the second quarter of 2026.” · word for word

Need for additional capital to fund operations

“We will need substantial additional capital in the future to support these efforts.” · word for word

Reliance on third-party manufacturers and CROs

“We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies and other biologics for our preclinical research, clinical trials, and if and when applicable, commercial product.” · word for word

Clinical trial success reduces pipeline risk but commercialization and regulatory approval risks remain.

“Positive topline results for ozekibart in chondrosarcoma; BLA submission planned for Q2 2026.”